{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:33:11Z","timestamp":1789115591494,"version":"build-2803163510"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>To combat the ongoing opioid crisis, policy makers and public health officials are developing novel policies to increase the availability of medications for opioid use disorder (OUD). An important question is to what extent geographic availability of opioid treatment programs (OTPs) is associated with treatment receipt. Understanding this association may help with developing additional policies to increase medication for OUD dispensing and improve population health outcomes.<\/jats:p><\/jats:sec>Objective<\/jats:title>To quantify trends in dispensing methadone to Medicare beneficiaries based on proximity to an OTP.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cross-sectional study analyzed 2020 Medicare fee-for-service claims for methadone for beneficiaries with a recent diagnosis of OUD merged with drive times to OTP locations. Medicare beneficiaries enrolled in a Part D prescription plan and diagnosed with OUD in any of the 3 quarters before and during the 2020 quarter of interest were examined.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Drive time between the centroid of a beneficiary\u2019s zip code and the closest OTP.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Quarterly methadone receipt among Medicare beneficiaries with a recent OUD diagnosis was assessed using logistic regression models.<\/jats:p><\/jats:sec>Results<\/jats:title>In 2020, there were 640\u202f706 Medicare beneficiaries with a recent OUD diagnosis (mean [SD] age, 62.5 [13.5] years; 55.6% female; 65.5% residing in an urban locality at the time of diagnosis). Of these beneficiaries, 9.6% lacked an OTP within a 60-minute drive time. The probability of a beneficiary receiving methadone decreased as the drive time from an OTP increased. Specifically, in urban areas, the likelihood of methadone receipt decreased by a relative 54% from a mean of 5.29% (national interval, 4.27%-6.52%) for beneficiaries who lived within a 5-minute drive of an OTP to 2.39% (national interval, 1.92%-2.98%) for those who lived within a 15-minute drive from an OTP. For rural beneficiaries, the likelihood of methadone receipt decreased by a relative 27% from a mean of 3.42% (national interval, 2.73%-4.28%) for a 5-minute drive time to 2.39% (national interval, 1.92%-2.98%) for a 15-minute drive time. Evidence of a threshold effect at a drive time of 20 minutes was observed for methadone receipt, after which the rate slowed and was similar between urban and rural beneficiaries.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>These findings suggest that the likelihood of methadone receipt may vary based on proximity to OTP facilities. Where OTPs are located may be a contributor to whether an individual receives methadone treatment.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.3099","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T21:28:24Z","timestamp":1743802104000},"page":"e253099","source":"Crossref","is-referenced-by-count":10,"title":["Medicare Beneficiary Receipt of Methadone by Drive Time to Opioid Treatment Programs"],"prefix":"10.1001","volume":"8","author":[{"given":"Jonathan","family":"Cantor","sequence":"first","affiliation":[{"name":"RAND, Santa Monica, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helin G.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"RAND, Santa Monica, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Kofner","sequence":"additional","affiliation":[{"name":"RAND, Arlington, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Lai","sequence":"additional","affiliation":[{"name":"RAND, Santa Monica, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Agniel","sequence":"additional","affiliation":[{"name":"RAND, Santa Monica, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosali I.","family":"Simon","sequence":"additional","affiliation":[{"name":"O\u2019Neill School of Public and Environmental Affairs, Indiana University, Bloomington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley D.","family":"Stein","sequence":"additional","affiliation":[{"name":"RAND, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin A.","family":"Taylor","sequence":"additional","affiliation":[{"name":"RAND, Santa Monica, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"22","key":"zoi250160r1","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1002\/cncr.31713","article-title":"The opioid epidemic in the United States-overview, origins, and potential solutions.","volume":"124","author":"Jones","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"zoi250160r2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.7326\/M20-1212","article-title":"Collision of the COVID-19 and addiction epidemics.","volume":"173","author":"Volkow","year":"2020","journal-title":"Ann Intern Med"},{"key":"zoi250160r3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.drugalcdep.2017.10.007","article-title":"Treatment for opioid use and outcomes in older adults: a systematic literature review.","volume":"182","author":"Carew","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"zoi250160r5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ypmed.2019.02.018","article-title":"Prescription opioid misuse among middle-aged and older adults in the United States, 2015-2016.","volume":"121","author":"Han","year":"2019","journal-title":"Prev Med"},{"issue":"5","key":"zoi250160r6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/jamapsychiatry.2022.5159","article-title":"Twenty-year trends in drug overdose fatalities among older adults in the US.","volume":"80","author":"Humphreys","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"zoi250160r8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/00952990.2019.1694536","article-title":"A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States.","volume":"46","author":"Lister","year":"2020","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"2","key":"zoi250160r9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1080\/10550887.2023.2165869","article-title":"Geographic variation in availability of opioid treatment programs across U.S. communities.","volume":"42","author":"Jehan","year":"2024","journal-title":"J Addict Dis"},{"key":"zoi250160r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108727","article-title":"Access to medication-assisted treatment in the United States: comparison of travel time to opioid treatment programs and office-based buprenorphine treatment.","volume":"224","author":"Amiri","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"zoi250160r11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ypmed.2015.04.017","article-title":"Interim treatment: bridging delays to opioid treatment access.","volume":"80","author":"Sigmon","year":"2015","journal-title":"Prev Med"},{"key":"zoi250160r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104141","article-title":"Typology of laws restricting access to methadone treatment in the United States: a latent class analysis.","volume":"119","author":"Conway","year":"2023","journal-title":"Int J Drug Policy"},{"issue":"6","key":"zoi250160r13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11920-017-0783-9","article-title":"Update on barriers to pharmacotherapy for opioid use disorders.","volume":"19","author":"Sharma","year":"2017","journal-title":"Curr Psychiatry Rep"},{"issue":"4","key":"zoi250160r14","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1080\/08897077.2020.1846149","article-title":"System-level factors shaping the implementation of \u201chub and spoke\u201d systems to expand MOUD in rural areas.","volume":"42","author":"Snell-Rood","year":"2021","journal-title":"Subst Abus"},{"issue":"3","key":"zoi250160r15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/1468-0009.12137","article-title":"Where is buprenorphine dispensed to treat opioid use disorders? the role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties.","volume":"93","author":"Stein","year":"2015","journal-title":"Milbank Q"},{"issue":"6","key":"zoi250160r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.6373","article-title":"Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder.","volume":"2","author":"Haffajee","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi250160r18","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/jgs.16281","article-title":"Help is on the way: Medicare coverage of opioid treatment programs.","volume":"68","author":"Felix","year":"2020","journal-title":"J Am Geriatr Soc"},{"key":"zoi250160r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209247","article-title":"Introduction of Medicare coverage in opioid treatment programs: Findings from the first three years.","volume":"158","author":"Abraham","year":"2024","journal-title":"J Subst Use Addict Treat"},{"issue":"5","key":"zoi250160r21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.14328","article-title":"Trends in methadone dispensing for opioid use disorder after Medicare payment policy changes.","volume":"6","author":"Taylor","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"7","key":"zoi250160r22","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.1907","article-title":"Medicare payment for opioid treatment programs.","volume":"5","author":"Nakamoto","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"7","key":"zoi250160r23","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1377\/hlthaff.2023.00148","article-title":"Changes in county-level access to medications for opioid use disorder after Medicare coverage of methadone treatment began.","volume":"42","author":"Harris","year":"2023","journal-title":"Health Aff (Millwood)"},{"key":"zoi250160r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108131","article-title":"Geographic proximity to buprenorphine treatment providers in the U.S.","volume":"213","author":"Langabeer","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"zoi250160r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109107","article-title":"Population-based estimates of geographic accessibility of medication for opioid use disorder by substance use disorder treatment facilities from 2014 to 2020.","volume":"229","author":"Cantor","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi250160r26","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1080\/08897077.2021.1986882","article-title":"A bridge too far? distance to waivered physicians and utilization of buprenorphine treatment for opioid use disorder in West Virginia Medicaid.","volume":"43","author":"Saloner","year":"2022","journal-title":"Subst Abus"},{"key":"zoi250160r27","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100130","article-title":"Critical access medication for opioid use disorder (MOUD) treatment facilities in the continental United States.","volume":"6","author":"Pollack","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"issue":"2","key":"zoi250160r28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.0209","article-title":"Accessibility of opioid treatment programs based on conventional vs perceived travel time measures.","volume":"7","author":"Kim","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"13","key":"zoi250160r29","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jama.2019.12562","article-title":"Drive times to opioid treatment programs in urban and rural counties in 5 US states.","volume":"322","author":"Joudrey","year":"2019","journal-title":"JAMA"},{"issue":"11","key":"zoi250160r30","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1001\/jamapsychiatry.2020.1624","article-title":"Comparison of driving times to opioid treatment programs and pharmacies in the US.","volume":"77","author":"Kleinman","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"zoi250160r31","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamapsychiatry.2020.1511","article-title":"Methadone for opioid use disorder-decades of effectiveness but still miles away in the US.","volume":"77","author":"Joudrey","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"zoi250160r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107968","article-title":"Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: a cross-sectional study.","volume":"211","author":"Joudrey","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"zoi250160r33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1012307","article-title":"Spatial inequities in access to medications for treatment of opioid use disorder highlight scarcity of methadone providers under counterfactual scenarios.","volume":"20","author":"Tatara","year":"2024","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"zoi250160r34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/29767342231208516","article-title":"Utilization of medications for opioid use disorder among West Virginia Medicaid enrollees following Medicaid coverage of methadone.","volume":"45","author":"Harris","year":"2024","journal-title":"Subst Use Addctn J"},{"key":"zoi250160r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2023.102297","article-title":"Travel for medical or dental care by race\/ethnicity and rurality in the U.S.: findings from the 2001, 2009 and 2017 National Household Travel Surveys.","volume":"35","author":"Akinlotan","year":"2023","journal-title":"Prev Med Rep"},{"issue":"398","key":"zoi250160r37","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/01621459.1987.10478440","article-title":"Generalized additive models: some applications.","volume":"82","author":"Hastie","year":"1987","journal-title":"J Am Stat Assoc"},{"issue":"7","key":"zoi250160r39","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.23708","article-title":"Changes in buprenorphine and methadone supplies in the US during the COVID-19 pandemic.","volume":"5","author":"Chen","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"166","key":"zoi250160r40","first-page":"1","article-title":"2013 NCHS urban-rural classification scheme for counties.","author":"Ingram","year":"2014","journal-title":"Vital Health Stat 2"},{"issue":"2","key":"zoi250160r41","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.amepre.2022.01.021","article-title":"Substance use disorders among Medicare beneficiaries: prevalence, mental and physical comorbidities, and treatment barriers.","volume":"63","author":"Parish","year":"2022","journal-title":"Am J Prev Med"},{"issue":"7","key":"zoi250160r42","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3109\/10826084.2014.891615","article-title":"Barriers to substance abuse treatment in rural and urban communities: counselor perspectives.","volume":"49","author":"Pullen","year":"2014","journal-title":"Subst Use Misuse"},{"key":"zoi250160r43","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/948789","article-title":"Distance traveled and cross-state commuting to opioid treatment programs in the United States.","volume":"2011","author":"Rosenblum","year":"2011","journal-title":"J Environ Public Health"},{"key":"zoi250160r44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jsat.2018.07.006","article-title":"Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington.","volume":"93","author":"Amiri","year":"2018","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"zoi250160r45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/29767342231208516","article-title":"Utilization of medications for opioid use disorder among West Virginia Medicaid enrollees following Medicaid coverage of methadone.","volume":"45","author":"Harris","year":"2024","journal-title":"Subst Use Addctn J"},{"key":"zoi250160r46","doi-asserted-by":"publisher","first-page":"S413","DOI":"10.1097\/MLR.0000000000001612","article-title":"Which definition of rurality should I use?: the relative performance of 8 federal rural definitions in identifying rural-urban disparities.","volume":"59","author":"Long","year":"2021","journal-title":"Med Care"},{"issue":"2","key":"zoi250160r47","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jval.2020.08.2098","article-title":"Disparities in access to opioid treatment programs and office-based buprenorphine treatment across the rural-urban and area deprivation continua: a US nationwide small area analysis.","volume":"24","author":"Amiri","year":"2021","journal-title":"Value Health"},{"issue":"3","key":"zoi250160r48","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s11606-022-07891-w","article-title":"Buprenorphine treatment episodes during the first year of COVID: a retrospective examination of treatment initiation and retention.","volume":"38","author":"Stein","year":"2023","journal-title":"J Gen Intern Med"},{"issue":"19","key":"zoi250160r49","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMsa2212412","article-title":"Racial inequality in receipt of medications for opioid use disorder.","volume":"388","author":"Barnett","year":"2023","journal-title":"N Engl J Med"},{"key":"zoi250160r38","doi-asserted-by":"crossref","DOI":"10.1201\/9781315370279","volume-title":"Generalized Additive Models: An Introduction With R","author":"Wood","year":"2017","edition":"2nd ed"},{"key":"zoi250160r4","unstructured":"Opioid overdoses and the limited treatment of opioid use disorder continue to be concerns for Medicare beneficiaries. US Department of Health and Human Services Office of the Inspector General. 2022. Accessed November 8, 2023. https:\/\/oig.hhs.gov\/oei\/reports\/OEI-02-22-00390.pdf"},{"key":"zoi250160r7","unstructured":"Opioid treatment program directory. Substance Abuse and Mental Health Services Administration. 2023. Accessed November 8, 2023. https:\/\/dpt2.samhsa.gov\/treatment\/directory.aspx"},{"key":"zoi250160r17","unstructured":"Support for patients and communities act. Congress.gov. 2018. Accessed December 3, 2024. https:\/\/www.congress.gov\/bill\/115th-congress\/house-bill\/6"},{"key":"zoi250160r19","doi-asserted-by":"crossref","unstructured":"Agniel? D, Cantor? JH, Maclean? JC, Simon? KI, Taylor? E. Insurance coverage and provision of opioid treatment: evidence from Medicare. National Bureau of Economic Research working paper 31884. November 2023. Accessed December 1, 2023. https:\/\/www.nber.org\/system\/files\/working_papers\/w31884\/w31884.pdf","DOI":"10.3386\/w31884"},{"key":"zoi250160r36","unstructured":"Opioid treatment program providers. Centers for Medicare & Medicaid Services. 2023. Accessed August 20, 2023. https:\/\/data.cms.gov\/provider-characteristics\/medicare-provider-supplier-enrollment\/opioid-treatment-program-providers"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2832137\/cantor_2025_oi_250160_1742918032.21309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T21:28:39Z","timestamp":1743802119000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2832137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.3099","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]}}}